Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Myriad Genetics
 More »

  • Top 40 Molecular Millionaires
    ... 11 25 Closing price on March 11: $52.55 #24. Peter D. Meldrum President and CEO, Myriad Genetics Total value of all shares: $78,773,550 26 1,871,995 shares of common stock as of ...
    9-19-2013
  • Gene Test Boom Faces Lawsuits
    Angelina Jolie went unmentioned during Myriad Genetics' August 13 conference call to ... Meldrum acknowledged that Myriad probably won't enjoy a similar boost from Hollywood in ...
    9-15-2013
  • Myriad, AstraZeneca Expand Collaboration on Olaparib
    Myriad Genetics expanded its collaboration with AstraZeneca, affirming that it will work to develop companion diagnostics for the olaparib Phase III clinical development program. ...
    9-4-2013
  • Gene Patent Decision: A Chemist's View
    The case before the Supreme Court is Association for Molecular Pathology et al v Myriad Genetics et al., 569 U.S. ____ (2013). Myriad was granted patents claiming, inter alia, "an ...
    9-1-2013
  • Gene Test Boom Faces Lawsuits
    Angelina Jolie went unmentioned during Myriad Genetics' August 13 conference call to ... Meldrum acknowledged that Myriad probably won't enjoy a similar boost from Hollywood in ...
    8-16-2013
  • Gene by Gene Acquires GE-Backed Arpeggi
    Gene to Gene made news June 13, the day the U.S. Supreme Court ruled against Myriad ... States for $995, compared with the $3,340 charged by Myriad for its BRAC Analysis test. ...
    8-7-2013
  • New Gene Patent Suit Sparks Talk of Trolls
    The BRAC Analysis developer is poised to spawn a Myriad of lawsuits. A month after a unanimous U.S. Supreme Court struck down seven Myriad Genetics patents tied to two breast ...
    7-23-2013
  • A Chemist's View of the Supreme Court's Gene Patent Decision
    The case before the Supreme Court is Association for Molecular Pathology et al v Myriad Genetics et al., 569 U.S. ____ (2013). Myriad was granted patents claiming, inter alia, "an ...
    7-18-2013
  • Myriad Sues Ambry, Gene by Gene Amid Confusion Over Supreme Court...
    When the Supreme Court handed down its ruling on contested patents held by Myriad Genetics in June, saying that "a naturally occurring DNA segment is a product of nature and not ...
    7-11-2013
  • Myriad to Perform BRCA Testing in CDx Deal with Tesaro
    Less than two weeks after the Supreme Court struck down its gene patents , Myriad Genetics has moved on, inking an agreement with cancer-focused biopharmaceutical company Tesaro to ...
    6-25-2013
  • A Myriad of Winners
    (AMP) a key victory in overturning Myriad Genetics' seven patents related to its ... And science has come a long way from when Myriad patented the BRCA genes, given the rise ...
    6-17-2013
  • What Did We Learn from Myriad?
    However, the Court ruled that complementary DNA (cDNA) is patent eligible because it is not naturally occurring ( Association for Molecular Pathology et al. v. Myriad Genetics, ...
    6-14-2013
  • Supreme Court Upends Patentability of Genes, but Not cDNA
    At issue is the validity of the seven patents issued to Myriad Genetics for BRCA 1 and 2 by the U.S. Patent and Trademark Office (USPTO). In 2009, 20 medical associations and ...
    6-13-2013
  • Editor's Note: Myriad, the Supreme Court, and Gene Patents
    GEN's John Sterling weighs in. The U.S. Supreme Court's decision on June 13 to invalidate Myriad Genetics' patents on two genes associated with hereditary breast and ovarian cancer ...
    6-13-2013
  • Myriad Genetics Trial: Your Thoughts?
    The U.S. Supreme Court just delivered a mixed decision for companies looking to patent human genes, ruling against Myriad Genetics' patent claims for breast cancer susceptibility ...
    6-13-2013

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Balancing Family and Career for Women Ph.D.s

Which changes made to academic culture are most likely to encourage women researchers to stay?

Suggest a Poll